Re: CRISPR/Cas9-Mediated Glycolate Oxidase Disruption is an Efficacious and Safe Treatment for Primary Hyperoxaluria Type I.
Publication
, Journal Article
Assimos, DG
Published in: J Urol
May 2019
Duke Scholars
Published In
J Urol
DOI
EISSN
1527-3792
Publication Date
May 2019
Volume
201
Issue
5
Start / End Page
853 / 854
Location
United States
Related Subject Headings
- Urology & Nephrology
- Hyperoxaluria, Primary
- Disease Models, Animal
- CRISPR-Cas Systems
- Animals
- Alcohol Oxidoreductases
- 3202 Clinical sciences
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Assimos, D. G. (2019). Re: CRISPR/Cas9-Mediated Glycolate Oxidase Disruption is an Efficacious and Safe Treatment for Primary Hyperoxaluria Type I. J Urol, 201(5), 853–854. https://doi.org/10.1097/01.JU.0000554109.94248.01
Assimos, Dean G. “Re: CRISPR/Cas9-Mediated Glycolate Oxidase Disruption is an Efficacious and Safe Treatment for Primary Hyperoxaluria Type I.” J Urol 201, no. 5 (May 2019): 853–54. https://doi.org/10.1097/01.JU.0000554109.94248.01.
Assimos DG. Re: CRISPR/Cas9-Mediated Glycolate Oxidase Disruption is an Efficacious and Safe Treatment for Primary Hyperoxaluria Type I. J Urol. 2019 May;201(5):853–4.
Assimos, Dean G. “Re: CRISPR/Cas9-Mediated Glycolate Oxidase Disruption is an Efficacious and Safe Treatment for Primary Hyperoxaluria Type I.” J Urol, vol. 201, no. 5, May 2019, pp. 853–54. Pubmed, doi:10.1097/01.JU.0000554109.94248.01.
Assimos DG. Re: CRISPR/Cas9-Mediated Glycolate Oxidase Disruption is an Efficacious and Safe Treatment for Primary Hyperoxaluria Type I. J Urol. 2019 May;201(5):853–854.
Published In
J Urol
DOI
EISSN
1527-3792
Publication Date
May 2019
Volume
201
Issue
5
Start / End Page
853 / 854
Location
United States
Related Subject Headings
- Urology & Nephrology
- Hyperoxaluria, Primary
- Disease Models, Animal
- CRISPR-Cas Systems
- Animals
- Alcohol Oxidoreductases
- 3202 Clinical sciences
- 1103 Clinical Sciences